← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 2006Last known activity
Mar 31, 2023
Timeline
2000s
- Jan 1, 2004
ZNA Antwerpen— Founded
Drugs by trial phase (10 distinct, 10 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Disease
- Eye Diseases
- Graft vs Host Disease
- Hodgkin Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma, Non-Hodgkin
- Mental Disorders
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms, Plasma Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Psychotic Disorders
- Schizophrenia
- Uveitis
Recent trials (12)
- NCT05569772CollaboratorPhase 3Mar 31, 2023
- NCT05033964Overall official - principal investigatorPhase 2Nov 30, 2021
- NCT04874961Lead sponsorPhase 4May 20, 2021
- NCT03871361CollaboratorPhase 2Apr 1, 2019
- NCT03043820CollaboratorPhase 3Aug 1, 2016
- NCT01428973CollaboratorPhase 2Sep 1, 2011
- NCT01045382CollaboratorPhase 2Jul 1, 2010
- NCT01045382Overall official - principal investigatorPhase 2Jul 1, 2010
- NCT01072071Lead sponsorN/AFeb 1, 2010
- NCT00603330CollaboratorPhase 2Jan 1, 2008
- NCT00603330Overall official - principal investigatorPhase 2Jan 1, 2008
- NCT00689000Overall official - principal investigatorPhase 1/Phase 2May 1, 2006
Details
- Founded
- Antwerp, BE Jan 1, 2004
- Last known activity
- Mar 31, 2023